Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Prueba de la adición de un fármaco contra el cáncer, la lenalidomida, al tratamiento de quimioterapia combinada habitual ("EPOCH") para la leucemia-linfoma de células T en adultos (ATL)

17 de noviembre de 2026 actualizado por: National Cancer Institute (NCI)

Un estudio de fase 1 de lenalidomida en combinación con quimioterapia EPOCH para la leucemia-linfoma de células T en adultos asociado al HTLV (ATLL)

This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate [Oncovin], cyclophosphamide, and doxorubicin hydrochloride [hydroxydaunorubicin hydrochloride], or "EPOCH") in treating adult T-cell leukemia-lymphoma. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma. Drugs used in chemotherapy, such as etoposide, vincristine, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving lenalidomide and the usual combination chemotherapy may work better in treating adult T-cell leukemia-lymphoma compared to the usual combination chemotherapy alone.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

PRIMARY OBJECTIVE:

I. To determine the safest and most tolerable dose and schedule of lenalidomide to combine with etoposide, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride) (EPOCH) chemotherapy in adult T-cell leukemia-lymphoma (ATL/ATLL).

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity. II. To determine if lenalidomide and EPOCH activity results in significant improvement in remission rates, duration of remissions, and overall survival (OS) as compared to historical controls.

III. To determine if lenalidomide and EPOCH activity correlates with T-cell receptor (TCR) pathway gene mutational spectrum.

IV. To determine effects of lenalidomide and EPOCH on human T-cell leukemia virus type 1 (HTLV-1) proviral deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) loads.

V. To determine effects of lenalidomide and EPOCH on HTLV-1 clonality.

OUTLINE: This is a dose-escalation study of lenalidomide followed by a dose-expansion study.

INDUCTION THERAPY: Patients receive lenalidomide orally (PO) once daily (QD) on days 1-14 of 21 day cycles or days 1-21 or 1-28 of 28 day cycles. Patients receive doxorubicin hydrochloride intravenously (IV) continuously on days 1-4, vincristine sulfate IV continuously on days 1-4, etoposide IV continuously on days 1-4, prednisone PO on days 1-5, and cyclophosphamide IV over 1-4 hours on day 5. Treatment repeats every 21 or 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

MAINTENANCE THERAPY: Patients with complete response (CR), partial response (PR), or stable disease (SD) may receive up to 2 additional cycles of lenalidomide, doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone, and cyclophosphamide at the discretion of the investigator and/or up to an additional 2 years of lenalidomide in the absence of disease progression or unacceptable toxicity.

Patients undergo bone marrow biopsy at baseline and as clinically indicated. Patients undergo positron emission tomography/computed tomography (PET/CT) or CT, tissue and blood sample collection throughout the trial and multigated acquistion scan (MUGA) and echocardiogram (ECHO) at screening.

After completion of study treatment, patients are followed up for 2 years from end of induction. Patients who do not continue on lenalidomide maintenance are followed every 3 months for up to 2 years from the end of induction, progression, withdrawal, or until death, whichever occurs first.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

30

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Reclutamiento
        • Emory University Hospital/Winship Cancer Institute
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 404-778-1868
        • Investigador principal:
          • Pamela B. Allen
      • Atlanta, Georgia, Estados Unidos, 30308
        • Reclutamiento
        • Emory University Hospital Midtown
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 888-946-7447
        • Investigador principal:
          • Pamela B. Allen
    • Missouri
      • City of Saint Peters, Missouri, Estados Unidos, 63376
        • Reclutamiento
        • Siteman Cancer Center at Saint Peters Hospital
        • Contacto:
        • Investigador principal:
          • Lee Ratner
      • Creve Coeur, Missouri, Estados Unidos, 63141
        • Reclutamiento
        • Siteman Cancer Center at West County Hospital
        • Contacto:
        • Investigador principal:
          • Lee Ratner
      • St Louis, Missouri, Estados Unidos, 63110
        • Reclutamiento
        • Washington University School of Medicine
        • Contacto:
        • Investigador principal:
          • Lee Ratner
      • St Louis, Missouri, Estados Unidos, 63129
        • Reclutamiento
        • Siteman Cancer Center-South County
        • Contacto:
        • Investigador principal:
          • Lee Ratner
    • New Jersey
      • Basking Ridge, New Jersey, Estados Unidos, 07920
        • Reclutamiento
        • Memorial Sloan Kettering Basking Ridge
        • Investigador principal:
          • Steven M. Horwitz
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 212-639-7592
      • Middletown, New Jersey, Estados Unidos, 07748
        • Reclutamiento
        • Memorial Sloan Kettering Monmouth
        • Investigador principal:
          • Steven M. Horwitz
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 212-639-7592
      • Montvale, New Jersey, Estados Unidos, 07645
        • Reclutamiento
        • Memorial Sloan Kettering Bergen
        • Investigador principal:
          • Steven M. Horwitz
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 212-639-7592
    • New York
      • Commack, New York, Estados Unidos, 11725
        • Reclutamiento
        • Memorial Sloan Kettering Commack
        • Investigador principal:
          • Steven M. Horwitz
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 212-639-7592
      • Harrison, New York, Estados Unidos, 10604
        • Reclutamiento
        • Memorial Sloan Kettering Westchester
        • Investigador principal:
          • Steven M. Horwitz
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 212-639-7592
      • Mineola, New York, Estados Unidos, 11501
        • Suspendido
        • NYU Langone Hospital - Long Island
      • New York, New York, Estados Unidos, 10032
        • Reclutamiento
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
        • Investigador principal:
          • Jennifer E. Amengual
        • Contacto:
      • New York, New York, Estados Unidos, 10065
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center
        • Investigador principal:
          • Steven M. Horwitz
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 212-639-7592
      • New York, New York, Estados Unidos, 10065
        • Suspendido
        • NYP/Weill Cornell Medical Center
      • New York, New York, Estados Unidos, 10016
        • Suspendido
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Uniondale, New York, Estados Unidos, 11553
        • Reclutamiento
        • Memorial Sloan Kettering Nassau
        • Investigador principal:
          • Steven M. Horwitz
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 212-639-7592
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Reclutamiento
        • Ohio State University Comprehensive Cancer Center
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 800-293-5066
          • Correo electrónico: Jamesline@osumc.edu
        • Investigador principal:
          • Jonathan E. Brammer
    • Virginia
      • Richmond, Virginia, Estados Unidos, 23298
        • Reclutamiento
        • VCU Massey Comprehensive Cancer Center
        • Investigador principal:
          • Bruce O. Hough
        • Contacto:
          • Site Public Contact
          • Número de teléfono: 804-628-6430
          • Correo electrónico: CTOclinops@vcu.edu

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed CD2+, CD3+, or CD4+ acute, lymphoma or poor-risk chronic subtypes of ATLL including previously untreated or previously treated individuals who have received no more than 1 previous cycle of EPOCH, cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), or cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE)

  • Patients previously treated with azidothymidine (AZT), interferon (IFN), bexarotene, or mogamulizumab are eligible. Patients with stable disease at high risk of relapse from prior non-combination chemotherapy containing treatment are eligible to participate

  • Documentation of HTLV infection by enzyme-linked immunosorbent assay (ELISA) in individuals with confirmation of HTLV-1 infection (by immunoblot or polymerase chain reaction [PCR]) or a consistent clinical picture (including two of three of: 1) CD4+ leukemia or lymphoma, 2) hypercalcemia, and/or 3) Japanese, Caribbean, or South American birthplace) is required for enrollment. Confirmation of HTLV-1 infection is required to continue the subject on protocol after the first cycle of therapy. Patients will be enrolled based on reports from local or referral labs (e.g., Mayo Clinic or LabCorp). Confirmation will be performed by Ratner Lab at Washington University, retrospectively, but this is not a Clinical Laboratory Improvement Amendments (CLIA) assay and is not reimbursed by insurance

  • Age ≥ 18 years

    • Because no dosing or adverse event (AE) data are currently available on the use of lenalidomide in combination with EPOCH in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Absolute neutrophil count >= 1,000/mm^3 unless decreased due to bone marrow (BM) involvement with lymphoma

  • Platelets >= 100,000/mm^3 unless decreased due to BM involvement with lymphoma

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN), if potentially due to lymphoma, in the dose-expansion cohort, the first cycle may be given without lenalidomide and if transaminitis and bilirubinemia improves to meet parameters, participant may be enrolled

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x institutional ULN, if potentially due to lymphoma, in the dose-expansion cohort, the first cycle may be given without lenalidomide and if transaminitis and bilirubinemia improve to meet parameters, participant may be enrolled

  • Creatinine =< institutional ULN OR glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression

  • Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

  • Patients must have a life expectancy > 12 weeks

  • Patients must have no serious active infection requiring therapy at the time of study entry

  • Patients must not require the concurrent use of chemotherapy, interferon, zidovudine, arsenic, radiation therapy, or other specific anti-tumor therapy, during the course of this study

  • The effects of lenalidomide on the developing human fetus are unknown. Immunodulatory derivative (immunomodulatory imide drug [IMiD]) agents as well as other therapeutic agents used in this trial are known to be teratogenic. Females of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to, and again within 24 hours of starting lenalidomide, and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counselled at a minimum of every 28 days about pregnancy precautions and risk of fetal exposure. Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study, she should inform her treating physician immediately. FCBP must use adequate contraception for at least 28 days after discontinuation from study. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for at least 28 days after discontinuation from study

  • Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible

Exclusion Criteria:

  • Patients that have received prior IMiDs for treatment of ATLL
  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
  • Patients who have not recovered to grade 1 or better from AEs due to prior anti-cancer therapy (not including cycle 1 of EPOCH, CHOP, or CHOPE if received off protocol) within 14 days prior to enrollment, with the exception of alopecia
  • Patients who are receiving any other investigational agents or have received them within 14 days prior to enrollment
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide or other agents used in study. Anaphylactic reactions including death have been reported with cyclophosphamide. Possible cross-sensitivity with other alkylating agents can occur
  • Patients unable to take aspirin or prophylactic doses of low molecular weight heparin or direct oral anticoagulants
  • Patients with urinary outflow obstruction (contraindication for cyclophosphamide)
  • Patients with any form of demyelinating disease should not be given vincristine sulfate injection
  • Patients with uncontrolled intercurrent illness
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because lenalidomide is an IMiD agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lenalidomide, breastfeeding should be discontinued if the mother is treated with lenalidomide. These potential risks may also apply to other agents used in this study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Treatment (lenalidomide, EPOCH)

See Detailed Description.

Given IV

Otros nombres:
  • Citoxano
  • CTX
  • (-)-ciclofosfamida
  • 2H-1,3,2-oxazafosforina, 2-[bis(2-cloroetil)amino]tetrahidro-, 2-óxido, monohidrato
  • Carloxano
  • Ciclofosfamida
  • Cicloxal
  • Clafen
  • Clafeno
  • CP monohidrato
  • Célula CYCLO
  • Cicloblastina
  • Ciclofosfano
  • Monohidrato de ciclofosfamida
  • Ciclostina
  • Citofosfano
  • Fosfaseron
  • Genoxal
  • Genuina
  • Ledoxina
  • Mitoxano
  • Neosar
  • Revimmune
  • Siklofosfamid
  • WR-138719
  • Asta B 518
  • B-518
  • B 518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

Otros nombres:
  • Adriamicina
  • 5,12-naftacenodiona, 10-[(3-amino-2,3,6-tridesoxi-alfa-L-lixo-hexopiranosil)oxi]-7,8, 9,10-tetrahidro-6,8,11-trihidroxi -8-(hidroxiacetil)-1-metoxi-, clorhidrato, (8S-cis)- (9CI)
  • ADM
  • Adriacina
  • Clorhidrato de adriamicina
  • Adriamicina SLP
  • Adriamicina RDF
  • ADRIAMICINA, CLORHIDRATO
  • Adriblastina
  • Adrímedac
  • Clorhidrato de doxorrubicina
  • DOX
  • CÉLULA DOXO
  • Doxolema
  • Doxorrubicina.HCl
  • Doxorrubina
  • Farmiblastina
  • FI 106
  • FI-106
  • hidroxidaunorrubicina
  • Rubéx
  • FI106

Given PO

Otros nombres:
  • Deltasona
  • Orasona
  • .delta.1-cortisona
  • 1, 2-deshidrocortisona
  • Adasona
  • Cortancilo
  • Dacortina
  • DeCortin
  • Decortisilo
  • Decoración
  • Delta 1-cortisona
  • Domo delta
  • Deltacorteno
  • Deltacortisona
  • Deltadehidrocortisona
  • Deltison
  • Deltra
  • Econosona
  • Lisacort
  • Meprosona-F
  • Metacortandracina
  • Meticorten
  • Ofisolona
  • Panafcort
  • Panasol-S
  • Paracorto
  • Perrigo Prednisona
  • PRED
  • Predicor
  • Predicorten
  • Prednicen-M
  • Prednicort
  • Prednidib
  • Prednilonga
  • Prednimento
  • Prednisona Intensol
  • Prednisón
  • Prednitona
  • Promifen
  • Rayos
  • Servisona
  • SK-Prednisona

Given PO

Otros nombres:
  • CC-5013
  • Revlimid
  • CC5013
  • CDC 501
  • CC 5013

Undergo bone marrow biopsy

Otros nombres:
  • Biopsia de Médula Ósea
  • Biopsia De Médula Ósea

Given IV

Otros nombres:
  • Oncovin
  • Kyocristina
  • Sulfato de leurocristina
  • Leurocristina, sulfato
  • Vincasar
  • Vincósido
  • Vincrex
  • Vincristina, sulfato

Undergo ECHO

Otros nombres:
  • Ecocardiografía
  • CE

Undergo MUGA

Otros nombres:
  • Exploración de la piscina de sangre
  • Angiografía con radionúclidos de equilibrio
  • Imagen de piscina de sangre cerrada
  • MUGA
  • Ventriculografía con radionúclidos
  • RNVG
  • Escaneo SIMA
  • Escaneo de adquisición sincronizado de múltiples puertas
  • Escaneo MUGA
  • Escaneo de adquisición de puertas múltiples
  • Exploración de ventriculograma con radionúclidos
  • Escaneo de grupo de corazón cerrado
  • Escaneo RNV

Given IV

Otros nombres:
  • Demetil Epipodofilotoxina Etilidina Glucósido
  • EPEG
  • Último
  • Toposar
  • Vepesid
  • PV 16
  • PV 16-213
  • VP-16
  • VP-16-213
  • VP16
  • Vicepresidente 16213
  • VP-16213
  • VP16213

Undergo PET/CT

Otros nombres:
  • Imágenes médicas, tomografía por emisión de positrones
  • MASCOTA
  • Escaneo de mascotas
  • Tomografía por emisión de positrones
  • Tomografía de emisión de positrones
  • PT
  • Tomografía por emisión de positrones (procedimiento)

Undergo PET/CT or CT

Otros nombres:
  • Connecticut
  • GATO
  • Análisis de gato
  • Tomografía Axial Computarizada
  • Tomografía axial computarizada
  • Tomografía computarizada
  • tomografía
  • Tomografía axial computarizada (procedimiento)
  • Tomografía computarizada (TC)
  • Escaneo de gato de diagnóstico
  • Tipo de servicio de escaneo de gato de diagnóstico

Undergo tissue and blood sample collection

Otros nombres:
  • Recolección de muestras biológicas
  • Muestra biológica recolectada
  • Coleccion de especimenes
  • Recolección de muestras

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Maximum tolerated dose (MTD)
Periodo de tiempo: Up to the end of induction therapy

Will determine the MTD for lenalidomide in combination with etoposide, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride) (EPOCH) chemotherapy.

Up to the end of induction therapy

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall response rate
Periodo de tiempo: Up to 2 years after completion of study treatment

Will be summarized using descriptive statistics. Binomial proportions and their 95% confidence intervals will be used to estimate the response rates of therapy.

Up to 2 years after completion of study treatment
Duration of response
Periodo de tiempo: From the time measurement criteria are met for complete response or partial response until the first date that recurrent or progressive disease is objectively documented, assessed up to 2 years after completion of study treatment

Will be summarized using descriptive statistics. The Kaplan-Meier method will be used to evaluate the response duration.

From the time measurement criteria are met for complete response or partial response until the first date that recurrent or progressive disease is objectively documented, assessed up to 2 years after completion of study treatment
Progression-free survival
Periodo de tiempo: Up to 2 years after completion of study treatment

Profession-free survival will be determined by the number of weeks from the time of initiation of therapy until there is evidence of tumor progression by acute T-cell leukemia (ATL) response criteria of Tuskasaki, 2009.

Up to 2 years after completion of study treatment
Overall survival
Periodo de tiempo: Up to 2 years after completion of study treatment

Over survival will be determined by the number of week of weeks from the time of initiation of therapy until death.

Up to 2 years after completion of study treatment
T-cell receptor pathway gene mutational spectrum
Periodo de tiempo: Up to 2 years after completion of study treatment

T-cell receptor pathway gene mutation will be determined by targeted next-generation sequence after hybridization to specific oligonucleotide capture probes corresponding to the sequence most commonly mutation in ATL as defined by Kataoka et al, 2015.

Up to 2 years after completion of study treatment
Human T-cell leukemia virus type 1 (HTLV-1) proviral deoxyribonucleic acid and ribonucleic acid loads
Periodo de tiempo: Up to 2 years after completion of study treatment

Analysis of variance methods will be used to evaluate the effects of treatment and time on the viral load measurements, as well as measurements of viral transcripts.

Up to 2 years after completion of study treatment
HTLV-1 clonality
Periodo de tiempo: Up to 2 years after completion of study treatment

HTLV-1 clonality will be determined by next generation sequence analysis of viral integration sites resulting in a distribution of the number of reads for each integration site plotted per integration site, as described by Gillet et al. 2011.

Up to 2 years after completion of study treatment
Incidence of toxicities
Periodo de tiempo: Up to the end of induction therapy

The incidence of toxicities will be estimated using the binomial proportion and its 95% confidence interval.

Up to the end of induction therapy

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Lee Ratner, Yale University Cancer Center LAO

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

31 de agosto de 2021

Finalización primaria (Estimado)

30 de junio de 2027

Finalización del estudio (Estimado)

30 de junio de 2027

Fechas de registro del estudio

Enviado por primera vez

6 de marzo de 2020

Primero enviado que cumplió con los criterios de control de calidad

6 de marzo de 2020

Publicado por primera vez (Actual)

9 de marzo de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de noviembre de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • NCI-2020-01535
  • UM1CA186689 (Subvención/contrato del NIH de EE. UU.)
  • NCI-2020-01535 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
  • 10335 (Otro identificador: CTEP)
  • UM1CA186704 (Subvención/contrato del NIH de EE. UU.)
  • 10335 (Otro identificador: Yale University Cancer Center LAO)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .